Press center

On August 14, 2019, NANOLEK LLC withdrew from the list of RUSNANO portfolio companies, doubling the previously received state investment. By 2014, the company had received a total of RUB 1.28 billion in government investment through RUSNANO. The total investment in the creation of the Russian high-tech biopharmaceutical company stood at RUB 6 billion.

The profit that the Russian Federation will receive from the deal will allow further effective use of funds allocated for national development and a leading position in the world markets for high-tech products.

Vladimir Khristenko, President of NANOLEK: “Today we can say that the NANOLEK project, led by RUSNANO, has reached the life-cycle stage of an investment project and has achieved its assigned capacity, thus clearly demonstrating its potential. That is why the corporation is leaving the shareholding structure.

The company has gained invaluable experience from collaborating with the largest state corporation, government support, and access to the expertise necessary for the success of the business.”